Skip to content

H.R. 6802 · 118th Congress (2023–2025)

RAPID Reserve Act

This bill requires the Department of Health and Human Services to contract with drug manufacturers to ensure adequate supplies of critical drugs that have vulnerable supply chains. (Under the bill, drugs are considered critical if they are likely to be needed during a public health emergency or if a shortage would pose a significant threat to the health care system or at-risk populations.)

Contracted drug manufacturers must agree to (1) maintain at least a 6-month reserve of the active ingredient in a critical drug and of the finished product and to regularly replenish these reserves, (2) produce the ingredient and drug in a manner and quantity as specified in the contract, and (3) agree to transfer portions of the reserve, if necessary, to other manufacturers to meet manufacturing needs and allow HHS to control the allocation of reserves in the event of a public health emergency or other threat.

HHS must publish a list of critical drugs and issue guidance on the criteria for determining this list and awarding contracts. HHS must give preference to domestic manufacturers for contracts.

In addition, the Government Accountability Office must report on the capacity of domestic manufacturing with respect to critical drugs, including the ability to manufacture different dosage forms and drugs with various characteristics.

Show official title

To improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 6802’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Angie Craig (D-MN-2)
Cosponsors
6 cosponsors

2 original · 4 later

1 R · 5 D

  1. Rep. Abigail Davis Spanberger (D-VA-7)· Original · Dec 14, 2023
  2. Rep. Jefferson Van Drew (R-NJ-2)· Original · Dec 14, 2023
  3. Del. Eleanor Holmes Norton (D-DC)· Later · Mar 7, 2024
  4. Rep. Chrissy Houlahan (D-PA-6)· Later · Mar 12, 2024
  5. Rep. Elissa Slotkin (D-MI-7)· Later · May 6, 2024
  6. Rep. Darren Soto (D-FL-9)· Later · Aug 16, 2024
Policy area
Health
Subjects
  • Congressional oversight
  • Drug safety, medical device, and laboratory regulation
  • Government information and archives
  • Government studies and investigations
  • Manufacturing
  • Prescription drugs
  • Public contracts and procurement
  • Strategic materials and reserves

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Dec 14, 2023 – Dec 15, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Dec 14, 2023
  2. HouseHealthReferred Dec 15, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (3)
  1. RAPID Reserve Act

    Display title, Short title · Introduced in House

  2. Rolling Active Pharmaceutical Ingredient and Drug Reserve Act

    Short title · Introduced in House

  3. To improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies.

    Official title · Introduced in House